Yet for all the additional knowledge that has been acquired, the outcomes of epilepsy treatment, particularly MTLE, remain in the main stagnant. There is as yet no active intervention to prevent progression of epilepsy either from the "initial insult" to the "latency period," or from the latency period to chronic epilepsy. The question follows then: what is the benefit of large-scale gene expression profiling? Is the accumulation of knowledge of benefit to the treating epileptologist or does it create more confusion in the treatment of this already complex condition?